Suppr超能文献

全身照射和异基因干细胞移植后肺部原因导致的移植相关死亡率的预测与预防

Prediction and prevention of transplant-related mortality from pulmonary causes after total body irradiation and allogeneic stem cell transplantation.

作者信息

Savani Bipin N, Montero Aldemar, Wu Colin, Nlonda Nene, Read Elizabeth, Dunbar Cynthia, Childs Richard, Solomon Scott, Barrett A John

机构信息

Stem Cell Allotransplant Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.

出版信息

Biol Blood Marrow Transplant. 2005 Mar;11(3):223-30. doi: 10.1016/j.bbmt.2004.12.328.

Abstract

Between July 1997 and August 2004, 146 consecutive patients with hematologic malignancies received a T cell-depleted peripheral blood stem cell transplant from an HLA-identical sibling by using total body irradiation (TBI) and cyclophosphamide conditioning regimens. Eighty-five patients received 13.6 Gy of TBI with no lung shielding, and 61 received lung shielding (total lung dose, 6-12 Gy). Ninety-four patients (65.5%) had standard-risk disease; the remainder had more advanced disease or unfavorable diagnoses. Of the 21 transplant-related deaths, 14 were from pulmonary causes (10 idiopathic pulmonary syndromes and 4 from infection) that occurred at a median of 90 days (range, 23-238 days) after transplantation. Independent risk factors for pulmonary transplant-related mortality (PTRM) were pretransplantation diffusion capacity for carbon monoxide (relative risk, 5.7 for diffusion capacity for carbon monoxide <85%), smoking (relative risk, 5.0), and CD34 cell dose (relative risk, 9.4 for a CD34 dose of <5 x 10(6) cells per kilogram). Patients receiving lung shielding had significantly lower PTRM (3.3% versus 14.1%; P = .02) and better overall survival (70% +/- 6% versus 52% +/- 5%; P = .04), but lung shielding was not a significant independent factor for determining PTRM. These results suggest that pulmonary mortality after TBI-based preparative regimens is predictable and that higher CD34 cell doses can reduce the risk.

摘要

1997年7月至2004年8月期间,146例连续性血液系统恶性肿瘤患者接受了来自 HLA 相同同胞的 T 细胞去除外周血干细胞移植,采用全身照射(TBI)和环磷酰胺预处理方案。85例患者接受了13.6 Gy 的 TBI,未进行肺部屏蔽,61例接受了肺部屏蔽(全肺剂量6 - 12 Gy)。94例患者(65.5%)患有标准风险疾病;其余患者病情更进展或诊断不佳。在21例与移植相关的死亡中,14例死于肺部原因(10例特发性肺部综合征和4例感染),发生在移植后中位时间90天(范围23 - 238天)。肺部移植相关死亡率(PTRM)的独立危险因素为移植前一氧化碳弥散能力(一氧化碳弥散能力<85%时相对风险为5.7)、吸烟(相对风险为5.0)和 CD34细胞剂量(CD34剂量<5×10⁶ 细胞/千克时相对风险为9.4)。接受肺部屏蔽的患者PTRM显著更低(3.3%对14.1%;P = 0.02)且总生存率更好(70%±6%对52%±5%;P = 0.04),但肺部屏蔽不是决定PTRM的显著独立因素。这些结果表明,基于TBI的预处理方案后的肺部死亡率是可预测的,且更高的CD34细胞剂量可降低风险。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验